ACHM

Achieve announces the close of $173.6M HELOC securitization

Retrieved on: 
Thursday, October 19, 2023
Sale, Jules Kroll, Class D, FCCF, AAA, Entrepreneurship, HELOC, Environment, Risk, ACHM, Jefferies, SEC Rule 144A, Uncertainty, SAN, Security (finance), Bank

SAN MATEO, Calif., Oct. 19, 2023 /PRNewswire/ -- Achieve, the leader in digital personal finance, announces the Oct. 18, close of a AAA-rated securitization backed by $173.6 million in newly originated home equity lines of credit (HELOCs).

Key Points: 
  • SAN MATEO, Calif., Oct. 19, 2023 /PRNewswire/ -- Achieve , the leader in digital personal finance, announces the Oct. 18, close of a AAA-rated securitization backed by $173.6 million in newly originated home equity lines of credit (HELOCs).
  • The securitization, ACHM Trust 2023-HE2, consists of three classes of rated notes and two classes of unrated notes backed by 3,234 HELOCs originated by Achieve Home Loans.
  • The deal is the third HELOC securitization sponsored by Freedom Consumer Credit Fund, an investment fund managed by Freedom Financial Asset Management, LLC (FFAM), an Achieve company.
  • "The Achieve fixed-rate HELOC can provide homeowners with certainty about their monthly payments to help them get back on track."

Achieve Announces the Close of Two, AAA-Rated Consumer Loan Securitizations

Retrieved on: 
Thursday, February 2, 2023
Uncertainty, CE, Jefferies, DBRS, SEC Rule 144A, ABS, ACHM, HELOC, Cross River Bank, BBB, Trust, Sale, Securitization, FCCF, Risk, Class, Jules Kroll, FreedomPlus, Credit Suisse, Person, SAN, Regulation, AAA, Employment, KBRA, Bank, Security (finance), Credit, AA

SAN MATEO, Calif., Feb. 2, 2023 /PRNewswire/ -- Achieve, the leader in digital personal finance, announces the close of two AAA-rated securitizations — one offering of $244.8 million in notes backed by Achieve Personal Loans; and a second offering of notes backed by approximately $152.7 million in newly originated home equity lines of credit (HELOCs). Both securitizations closed on January 31, 2023.

Key Points: 
  • The personal loan securitization, ACHV ABS Trust 2023-1PL, consists of four classes of rated notes backed by 15,788 unsecured consumer personal loans.
  • It is the 15th personal loan securitization by Freedom Consumer Credit Fund (FCCF), an investment fund managed by Freedom Financial Asset Management (FFAM), an Achieve company.
  • The underlying Achieve Personal Loans in the securitization were originated by bank partners Cross River Bank and Pathward, N.A.
  • Issuances across all FCCF-sponsored securitizations now total over $4.6 billion and total loan originations through the FFAM platform and Achieve Home Loans exceeds $8 billion.

Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation

Retrieved on: 
Thursday, December 1, 2022
Optogenetics, Delaware General Corporation Law, Communication, LON, Retina, Life, Partnership, Patient, Central nervous system disease, Annual report, Neurotology, Eastern Time Zone, Central nervous system, CNS, Applied Genetic Technologies Corporation, Therapy, CVR, AAV, ACHM, Acquisition, Security (finance), Pharmaceutical industry

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC or the Company) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the Offer) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (Syncona).

Key Points: 
  • GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC or the Company) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the Offer) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (Syncona).
  • The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware.
  • As a result of the merger, AGTC has become an indirect, wholly owned subsidiary of Syncona Limited.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.

Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation

Retrieved on: 
Tuesday, November 29, 2022
Optogenetics, Communication, LON, Retina, TIME, Life, Partnership, Patient, Central nervous system disease, Neurotology, Eastern Time Zone, Computershare, Transmittal document, Schedule, Central nervous system, CNS, Security (finance), COMMON, Letter, Applied Genetic Technologies Corporation, Therapy, CVR, Failure, AAV, Personal Information Agent, ACHM, Acquisition, Pharmaceutical industry

The tender offer has been extended until 5:00 p.m., Eastern Time, on November 30, 2022.

Key Points: 
  • The tender offer has been extended until 5:00 p.m., Eastern Time, on November 30, 2022.
  • The tender offer was previously scheduled to expire at 5:00 p.m., Eastern Time, on November 28, 2022.
  • All other terms and conditions of the tender offer remain unchanged during the extension period.
  • The tender offer is being extended in order to allow additional time for shareholders to tender their shares and for shares tendered by notice of guaranteed delivery to be received.

*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*

Retrieved on: 
Monday, November 28, 2022
Optogenetics, Communication, Bankruptcy, Retina, TIME, Patient, Central nervous system disease, Annual report, Neurotology, Schedule, Central nervous system, CNS, COMMON, Letter, Applied Genetic Technologies Corporation, Therapy, Failure, AAV, Personal Information Agent, ACHM, Acquisition, Security (finance), Holding company

We urge you to tender your shares in the offer.

Key Points: 
  • We urge you to tender your shares in the offer.
  • You should act prior to the deadline specified by your bank or broker but, in any case, before the tender offer expires TODAY, November 28, 2022, at 5:00 p.m. Eastern Time.
  • AGTCs Board of Directors has unanimously approved the transaction and recommends that stockholders accept the offer and tender their shares in the offer.
  • It is therefore important that you tender your shares in the offer.

*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*

Retrieved on: 
Tuesday, November 22, 2022
Optogenetics, Communication, Bankruptcy, Retina, TIME, Patient, Central nervous system disease, Annual report, Neurotology, Schedule, Central nervous system, CNS, COMMON, Letter, Applied Genetic Technologies Corporation, Therapy, Failure, AAV, Personal Information Agent, ACHM, Acquisition, Security (finance), Holding company

We urge you to tender your shares in the offer.

Key Points: 
  • We urge you to tender your shares in the offer.
  • You should act prior to the deadline specified by your bank or broker but, in any case, before the tender offer expires on November 28, 2022, at 5:00 p.m. Eastern Time.
  • AGTCs Board of Directors has unanimously approved the transaction and recommends that stockholders accept the offer and tender their shares in the offer.
  • It is therefore important that you tender your shares in the offer.

Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022

Retrieved on: 
Monday, November 14, 2022
Optogenetics, Communication, Bankruptcy, Retina, TIME, Patient, Central nervous system disease, Annual report, Neurotology, Schedule, Central nervous system, CNS, COMMON, Letter, Applied Genetic Technologies Corporation, Therapy, Failure, AAV, Personal Information Agent, ACHM, Acquisition, Security (finance), Holding company

You should act prior to the deadline specified by your bank or broker but, in any case, before the tender offer expires on November 28, 2022, at 5:00 p.m. Eastern Time.

Key Points: 
  • You should act prior to the deadline specified by your bank or broker but, in any case, before the tender offer expires on November 28, 2022, at 5:00 p.m. Eastern Time.
  • AGTCs Board of Directors has unanimously approved the transaction and recommends that stockholders accept the offer and tender their shares in the offer.
  • It is therefore important that you tender your shares in the offer.
  • Applied Genetic Technologies Corporation Contacts:

Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022

Retrieved on: 
Thursday, November 3, 2022
Neurotology, Central nervous system, Company, ACHM, Therapy, Applied Genetic Technologies Corporation, GLOBE, Letter, COMMON, Bankruptcy, Schedule, Nasdaq, Optogenetics, CNS, TIME, Failure, Central nervous system disease, Retina, Forward-looking statement, Ophthalmology, Acquisition, Technology, SEC, Achievement, Personal Information Agent, Patient, AAV, Communication, Management, Security (finance), Holding company

I am writing today urging you to tender your shares of AGTC common stock in the tender offer.

Key Points: 
  • I am writing today urging you to tender your shares of AGTC common stock in the tender offer.
  • Our board of directors unanimously voted in favor of this acquisition and unanimously recommends that all AGTC stockholders tender their shares.
  • President and Chief Executive Officer, Applied Genetic Technologies Corporation
    AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • Applied Genetic Technologies Corporation Contacts:

Syncona Commences Tender Offer for All Outstanding Shares of Applied Genetic Technologies Corporation

Retrieved on: 
Wednesday, October 26, 2022
U.S. Securities and Exchange Commission, CNS, Tripura Merger Agreement, Letter, AS, Goal, WHEN, Applied Genetic Technologies Corporation, Achievement, Nasdaq, Tower of Power (transmitter), Communication, Patient, Technology, Plan, AAV, Letter of transmittal, Partnership, Central nervous system, Retina, Central nervous system disease, ACHM, CVR, THE, GLOBE, CVR Partners, Telephone, Optogenetics, Failure, Eastern Time Zone, Therapy, SEC, Life, Risk, TIME, Schedule, Schedule TO, Computershare, Purchasing, Agreement, Neurotology, Security (finance), Cryptocurrency, Pharmaceutical industry

AGTCs board of directors unanimously approved the Merger Agreement and recommends that all stockholders tender their shares in the tender offer.

Key Points: 
  • AGTCs board of directors unanimously approved the Merger Agreement and recommends that all stockholders tender their shares in the tender offer.
  • Additionally, AGTC has filed with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 that includes the unanimous recommendation of AGTCs board of directors that AGTCs stockholders tender their shares in the tender offer.
  • Requests for documents and questions regarding the tender offer may be directed to Georgeson LLC by telephone at (800) 279-6913.
  • The tender offer transaction commenced by affiliates of Syncona is being made pursuant to a tender offer statement on Schedule TO (including the Offer to Purchase, a related Letter of Transmittal and other offer materials) filed by such affiliates of Syncona with the SEC.

Syncona to Acquire Applied Genetic Technologies Corporation

Retrieved on: 
Monday, October 24, 2022
Therapy, IRDS, ACHM, CVR, Failure, CVR Partners, Retina, Optogenetics, Achievement, Person, LON, TIME, Money transmitter, Schedule TO, GLOBE, Central nervous system, Risk, Review, Hand, EACH, Security (finance), Technology, Goal, AAV, Cyprus Securities and Exchange Commission, Applied Genetic Technologies Corporation, CNS, Schedule, Central nervous system disease, SEC, Life, COMMON, Patient, Letter of transmittal, Neurotology, Nasdaq, Partnership, Exercise, P.C, Letter, Cryptocurrency, Pharmaceutical industry, Syncona

We share AGTCs passion in developing life changing treatments for patients with diseases with no currently approved therapies, said Chris Hollowood, Chief Investment Officer of Syncona Investment Management Limited.

Key Points: 
  • We share AGTCs passion in developing life changing treatments for patients with diseases with no currently approved therapies, said Chris Hollowood, Chief Investment Officer of Syncona Investment Management Limited.
  • Syncona has significant expertise in AAV gene therapy, and in particular, a strong track record of building retinal gene therapy businesses.
  • Under the terms of the definitive agreement, an indirect subsidiary of Syncona Limited will initiate a tender offer to acquire all outstanding shares of AGTC common stock.
  • Applied Genetic Technologies Corporation Contacts: